Get the Stockscreener App
0.00
100.00%
-2.38
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
See More
Previous Close:
$2.38
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$114.97M
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
0.00
EPS:
-1.38
Net Cash Flow:
$-82.44M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$4.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
0.00 | 114.97M | 0 | -97.22M | -82.44M | -1.38 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
Cassava Sciences Stock Rises 1.8% - National Today
Cassava Sciences (NASDAQ:SAVA) Stock Price Up 1.8%Here's What Happened - MarketBeat
RSI Check: Is Cassava Sciences Inc backed by strong institutional buying2026 PreEarnings & Fast Entry Momentum Alerts - baoquankhu1.vn
Cassava Sciences says DOJ has closed probe into allegations around its Alzheimer’s program - MSN
Dow Update: What is the dividend yield of Cassava Sciences Inc Equity WarrantInsider Selling & Proven Capital Preservation Tips - baoquankhu1.vn
Cassava Sciences, Inc. (FLNA) - Minichart
Cassava Sciences Inc Share PriceShare CFDs - FOREX.com
Energy Moves: What is Cassava Sciences Inc Equity Warrants book value per share - baoquankhu1.vn
SAVA PE Ratio & Valuation, Is SAVA Overvalued - Intellectia AI
ETF Watch: What are the future prospects of Cassava Sciences Inc Equity WarrantPortfolio Risk Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urg - GuruFocus
Cassava Sciences, Inc. Common Stock (FLNA) Competitors - Meyka
FOMO Trade: Does Cassava Sciences Inc Equity Warrant offer margin of safety2026 Key Highlights & Expert Approved Momentum Ideas - baoquankhu1.vn
Trading Recap: Is Cassava Sciences Inc Equity Warrant subject to activist investor interest2026 Sentiment & Daily Stock Trend Watchlist - baoquankhu1.vn
Block Trades: Does Cassava Sciences Inc Equity Warrant have pricing powerMarket Sentiment Summary & Long-Term Growth Stock Strategies - baoquankhu1.vn
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - marketscreener.com
Cassava Sciences, Inc. Class Action: The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - marketscreener.com
Filana Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | PX91 | US14817C1071 - marketscreener.com
Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your RightsSAVA - marketscreener.com
Filana Therapeutics Inc (FLNA-Q) Profile - The Globe and Mail
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - marketscreener.com
Filana Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | SAVA * | US14817C1071 - marketscreener.com
FLNA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cassava Sciences Posts Earnings, Beats Estimates - National Today
Cassava Sciences (NASDAQ:SAVA) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Filana Therapeutics (NASDAQ: SAVA) pivots to TSC epilepsy amid FDA clinical hold - Stock Titan
Total equity of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Average basic shares outstanding of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Cassava Sciences, Inc. Cash Flow – BMV:FLNA - TradingView
Price to book ratio of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Free cash flow per share of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Long term debt to total equity ratio of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Cassava Sciences, Inc. Earnings and Revenue – BMV:FLNA - TradingView
Cassava Sciences, Inc. Balance Sheet – BMV:FLNA - TradingView
ETFs Investing in Cassava Sciences, Inc. Stocks - TradingView
FLNA Forecast — Price Target — Prediction for 2027 - TradingView
Filana Therapeutics (NASDAQ: FLNA) pivots to TSC epilepsy amid $91M loss - Stock Titan
Biotech that ditched Alzheimer's drug pivots to epilepsy, slashes R&D 62% - Stock Titan
Rate Cut: Can Cassava Sciences Inc beat the S P 500Global Markets & Growth Focused Entry Point Reports - baoquankhu1.vn
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
FLNA Stock Price and Chart — NASDAQ:FLNA - TradingView
Two new option listings and one option delisting on March 11th - TipRanks
Cassava Sciences Rebrands as Filana Therapeutics, Updates Ticker - The Globe and Mail
Filana Therapeutics, Inc. will Change its Ticker to FLNA from SAVA - marketscreener.com
Cassava Sciences, Inc. will Change its Ticker to FLNA from SAVA - marketscreener.com
Cassava Sciences, Inc. has Changed its Name to Filana Therapeutics, Inc - marketscreener.com
Investors Purchase Large Volume of Cassava Sciences Call Options (NASDAQ:SAVA) - MarketBeat
Filana Therapeutics (NASDAQ: FLNA) adopts new name and FLNA ticker - Stock Titan
Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. - cassavasciences.com
Filamin A-focused Filana Therapeutics replaces Cassava Sciences - Stock Titan
Aug Ideas: Will Cassava Sciences Inc outperform small cap indexesLong Setup & Daily Chart Pattern Signals - baoquankhu1.vn
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cassava Sciences Inc Stock (SAVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barry Richard | President & CEO |
Nov 20 '25 |
Buy |
2.76 |
150,000 |
414,000 |
938,060 |
| Barry Richard | President & CEO |
Nov 19 '25 |
Buy |
2.75 |
73,385 |
201,809 |
788,060 |
| Cook Robert Christopher | Chief Operating & Legal Office |
Sep 30 '25 |
Buy |
2.91 |
13,725 |
39,940 |
13,725 |
| Barry Richard | President & CEO |
Sep 22 '25 |
Buy |
2.28 |
7,172 |
16,352 |
714,675 |
| Barry Richard | President & CEO |
Sep 18 '25 |
Buy |
2.24 |
190,633 |
426,424 |
660,195 |
| Barry Richard | President & CEO |
Sep 19 '25 |
Buy |
2.29 |
47,308 |
108,319 |
707,503 |
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):